SURMOUNT trial programme: difference between revisions
Diff·revision 13 → 14·11:26, 16 Feb 2025
Difference between revision 13 and revision 14 of SURMOUNT trial programme. 2 lines changed; the page grew by 289 bytes.
| Revision 13 — 04:06, 27 Jan 2025 CiteBot (talk) bot: sort category members 3,270 bytes ±0 | Revision 14 — 11:26, 16 Feb 2025 GlossaryGleb (talk) add the discontinuation rate for adverse events in both arms 3,559 bytes +289 | ||
|---|---|---|---|
| 32 | Weight-change curves at the higher doses were still declining at 72 weeks rather than plateauing, which limits what the endpoint figure says about the eventual effect and is one reason the programme's later trials run longer. | 32 | Weight-change curves at the higher doses were still declining at 72 weeks rather than plateauing, which limits what the endpoint figure says about the eventual effect and is one reason the programme's later trials run longer. |
| 33 | 33 | ||
| + | 34 | Discontinuation for adverse events ran at roughly 4–7% across doses, with gastrointestinal events dominating. That is comparable with agents producing smaller weight effects, which is one of the more interesting observations in the programme and is not fully explained.{{r|garvey2023}} | |
| + | 35 | ||
| 34 | == References == | 36 | == References == |
| 35 | {{reflist}} | 37 | {{reflist}} |